Hong Kong
· Delayed Price · Currency is HKD Innovent Biologics Statistics
Total Valuation
Innovent Biologics has a market cap or net worth of HKD 68.02 billion. The enterprise value is 62.35 billion.
| Market Cap | 68.02B |
| Enterprise Value | 62.35B |
Important Dates
The next estimated earnings date is Thursday, November 28, 2024.
| Earnings Date | Nov 28, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Innovent Biologics has 1.63 billion shares outstanding. The number of shares has increased by 5.12% in one year.
| Shares Outstanding | 1.63B |
| Shares Change (YoY) | +5.12% |
| Shares Change (QoQ) | +2.45% |
| Owned by Insiders (%) | 7.04% |
| Owned by Institutions (%) | 46.47% |
| Float | 1.41B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.35 |
| PB Ratio | 5.07 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -45.28 |
| EV / Sales | 7.78 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.68, with a Debt / Equity ratio of 26.95.
| Current Ratio | 2.68 |
| Quick Ratio | 2.42 |
| Debt / Equity | 26.95 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -18.36 |
Financial Efficiency
Return on equity (ROE) is -11.04% and return on invested capital (ROIC) is -6.61%.
| Return on Equity (ROE) | -11.04% |
| Return on Assets (ROA) | -5.19% |
| Return on Capital (ROIC) | -6.61% |
| Revenue Per Employee | 1.52M |
| Profits Per Employee | -261,608 |
| Employee Count | 4,872 |
| Asset Turnover | 0.39 |
| Inventory Turnover | 2.13 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +24.17% in the last 52 weeks. The beta is 0.12, so Innovent Biologics's price volatility has been lower than the market average.
| Beta (5Y) | 0.12 |
| 52-Week Price Change | +24.17% |
| 50-Day Moving Average | 40.50 |
| 200-Day Moving Average | 39.21 |
| Relative Strength Index (RSI) | 57.32 |
| Average Volume (20 Days) | 5,459,133 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Innovent Biologics had revenue of HKD 8.01 billion and -1.38 billion in losses. Loss per share was -0.86.
| Revenue | 8.01B |
| Gross Profit | 5.73B |
| Operating Income | -1.70B |
| Pretax Income | -1.38B |
| Net Income | -1.38B |
| EBITDA | -1.44B |
| EBIT | -1.70B |
| Loss Per Share | -0.86 |
Balance Sheet
The company has 9.27 billion in cash and 3.60 billion in debt, giving a net cash position of 5.67 billion or 3.48 per share.
| Cash & Cash Equivalents | 9.27B |
| Total Debt | 3.60B |
| Net Cash | 5.67B |
| Net Cash Per Share | 3.48 |
| Equity (Book Value) | 13.35B |
| Book Value Per Share | 8.23 |
| Working Capital | 7.44B |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 71.58%, with operating and profit margins of -21.27% and -17.18%.
| Gross Margin | 71.58% |
| Operating Margin | -21.27% |
| Pretax Margin | -17.18% |
| Profit Margin | -17.18% |
| EBITDA Margin | -18.03% |
| EBIT Margin | -21.27% |
| FCF Margin | n/a |
Dividends & Yields
Innovent Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.12% |
| Shareholder Yield | -5.12% |
| Earnings Yield | -2.06% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |